ALLO vs. PROK, NVAX, VALN, PRME, HLVX, MESO, FATE, EXAI, ALEC, and TSHA
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include ProKidney (PROK), Novavax (NVAX), Valneva (VALN), Prime Medicine (PRME), HilleVax (HLVX), Mesoblast (MESO), Fate Therapeutics (FATE), Exscientia (EXAI), Alector (ALEC), and Taysha Gene Therapies (TSHA). These companies are all part of the "biological products, except diagnostic" industry.
ProKidney (NASDAQ:PROK) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
ProKidney currently has a consensus price target of $9.50, indicating a potential upside of 278.49%. Allogene Therapeutics has a consensus price target of $12.94, indicating a potential upside of 343.07%. Given ProKidney's stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than ProKidney.
51.6% of ProKidney shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 45.0% of ProKidney shares are held by company insiders. Comparatively, 27.4% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ProKidney has a net margin of 0.00% compared to ProKidney's net margin of -202,366.25%. Allogene Therapeutics' return on equity of 0.00% beat ProKidney's return on equity.
Allogene Therapeutics received 261 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 64.65% of users gave Allogene Therapeutics an outperform vote.
ProKidney has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
In the previous week, ProKidney had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 12 mentions for ProKidney and 3 mentions for Allogene Therapeutics. ProKidney's average media sentiment score of 0.89 beat Allogene Therapeutics' score of 0.47 indicating that Allogene Therapeutics is being referred to more favorably in the news media.
ProKidney has higher earnings, but lower revenue than Allogene Therapeutics. ProKidney is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ProKidney beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
